2021
Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study
Bhalla S, Bakouny Z, Schmidt A, Labaki C, Steinharter J, Tremblay D, Awad M, Kessler A, Haddad R, Evans M, Busser F, Wotman M, Curran C, Zimmerman B, Bouchard G, Jun T, Nuzzo P, Qin Q, Hirsch L, Feld J, Kelleher K, Seidman D, Huang H, Anderson-Keightly H, El Zarif T, Abou Alaiwi S, Rosenbloom T, Stewart P, Galsky M, Choueiri T, Doroshow D. Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. Lung Cancer 2021, 160: 78-83. PMID: 34461400, PMCID: PMC8284065, DOI: 10.1016/j.lungcan.2021.07.002.Peer-Reviewed Original ResearchConceptsCancer Outcomes StudyLung cancerSolid tumorsHematological malignanciesTreatment delayPerson visitsCare disruptionsOutcome studiesCOVID-19Cancer care disruptionsProspective cohort studyAcademic cancer centerContinuity of careCOVID-19 pandemicCOVID-19 diagnosisCohort studySystemic therapyTelehealth visitsOutpatient visitsCancer CenterPatient populationSevere outcomesSolid malignanciesPatientsProcedure delays
2017
Periprocedural Bleeding Risk Assessment in Chronic Liver Disease
Fortune B, Madoff D, May B. Periprocedural Bleeding Risk Assessment in Chronic Liver Disease. Digestive Disease Interventions 2017, 01: 306-312. DOI: 10.1055/s-0038-1629916.Peer-Reviewed Original ResearchAdvanced liver diseaseChronic liver diseaseLiver diseaseCLD patientsInternational normalized ratio testsBleeding Risk AssessmentLaboratory abnormalitiesUnnecessary transfusionsBlood productsInvasive proceduresProcedure delaysPatientsDiseaseCoagulopathyPotential harmRiskLaboratory testsBleedingTransfusionRisk assessmentAbnormalitiesClinicians
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply